CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond

The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. 

Professor Alan M. Palmer is an internationally recognised neuroscientist and prize-wining biotech entrepreneur, whose career has focussed on neurodegenerative disorders and their treatment. 

He has board level experience in several organisations and is currently a non-executive director of One Nucleus Ltd and the British Neuroscience Association. He is also (i)  co-founder and CEO of Elixa MediScience Ltd, (ii) and sits as an advisor on boards for several charitable and governmental organisations. 

Following a PhD and post-doctoral work at the Institute of Neurology in London, he became a faculty member at the University of Pittsburgh Medical Centre in the USA. 

In 2005, Alan was voted London Biotechnology Network Entrepreneur of the Year.

Alan’s scientific research has had a high impact, particularly in the areas of Alzheimer’s disease and traumatic brain injury. While working at Cerebrus/Vernalis, he led a major project, in collaboration with University College London, to discover novel sodium channel blockers as neuroprotective agents for stroke and other neurodegenerative disorders.

Alan has a BSc in Biochemistry from Warwick University, an MSc from Kings College London (Institute of Psychiatry) and a PhD from University College London (Institute of Neurology).

In the podcast we cover the history of disease and research, the social and economic impacts, the different modalities and developments in therapeutics, and what the future of research into care in this field holds. Palmer explains the intricacies of anti-amyloid medications in light of the recent therapeutic approvals, and what this could mean for patients today and in the future.